Wells Fargo & Company Reiterates “Equal Weight” Rating for Regulus Therapeutics (NASDAQ:RGLS)
Regulus Therapeutics (NASDAQ:RGLS – Get Free Report)‘s stock had its “equal weight” rating reissued by research analysts at Wells Fargo & Company in a note issued to investors on Thursday,Benzinga reports. They presently have a $9.00 price target on the biopharmaceutical company’s stock. Wells Fargo & Company‘s target price suggests a potential upside of 14.65% […]
Regulus Therapeutics (NASDAQ:RGLS – Get Free Report)‘s stock had its “equal weight” rating reissued by research analysts at Wells Fargo & Company in a note issued to investors on Thursday,Benzinga reports. They presently have a $9.00 price target on the biopharmaceutical company’s stock. Wells Fargo & Company‘s target price suggests a potential upside of 14.65% […]
